Peter Pisters, a sarcoma and pancreatic cancer surgeon and an MD Anderson expat who serves as president and CEO of University Health Network of Toronto, is set to become the fifth president of the Houston-based cancer center.
NCI is asking for $6.38 billion for fiscal year 2019—nearly $1 billion, or 12 percent, above FY17 appropriation levels—to fully fund promising research areas.
Ocugen Inc. said FDA has granted orphan drug designation for OCU300 (brimonidine tartrate) for the treatment of ocular graft versus host disease.
On behalf of FDA, on Aug. 25 the U.S. Marshals Service seized five vials of Vaccinia Virus Vaccine (Live), a vaccine reserved for people at high risk for smallpox, such as some members of the military. Each of the vials originally contained 100 doses of the vaccine, and although one vial was partially used, four of the vials were intact.
A SWOG study estimates that implementation of findings from that group's clinical trials has added 3.34 million years to the lives of cancer patients in the 60 years since its founding in 1956.
The Neuroendocrine Tumor Research Foundation announced a new round of scientific and clinical research grants, aimed at advancing the treatment of and the search for cures to neuroendocrine tumors.
FDA granted a regular approval to enasidenib (IDHIFA) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.
FDA approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia: newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.
FDA gave nivolumab (Opdivo) an accelerated approval for the treatment of patients 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
FDA has approved ibrutinib (Imbruvica) for adult patients with chronic graft versus host disease after failure of one or more lines of systemic therapy, making it the first FDA-approved therapy for the treatment of cGVHD.
